This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
BPC-157
A synthetic peptide derived from a naturally occurring gastric protein - researched for remarkable tissue repair, neuroprotection, and gut-brain axis modulation, increasingly used in the biohacking community for cognitive recovery.
Benefits
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) derived from a protein naturally found in human gastric juice. Discovered and extensively studied by Dr Predrag Sikiric's research group at the University of Zagreb in Croatia since the early 1990s, BPC-157 has been the subject of over 100 published studies demonstrating remarkable tissue repair and cytoprotective properties across multiple organ systems, including the brain.
In the central nervous system, BPC-157 has demonstrated neuroprotective effects in animal models of traumatic brain injury, stroke, and neurotoxicity. A 2019 study published in Current Neuropharmacology showed that BPC-157 protected against cuprizone-induced demyelination (a model of multiple sclerosis) and promoted remyelination. It modulates the dopaminergic, serotonergic, and GABAergic systems, with studies showing it can counteract both dopamine agonist and antagonist-induced behavioural disturbances. A 2014 study in Journal of Physiology - Paris demonstrated that BPC-157 enhanced serotonin synthesis in specific brain regions and counteracted serotonin-depleting drug effects. Its interaction with the nitric oxide system (both protective NO and reducing excess NO in neuroinflammation) and its ability to upregulate growth hormone receptors contribute to its neuroregenerative profile. While human clinical trials for neurological applications are limited, the breadth of preclinical evidence and growing anecdotal reports from the biohacking community have made it one of the most discussed peptides in nootropic circles.
- Nitric oxide system modulation: Interacts with both eNOS (protective) and iNOS (inflammatory) pathways, promoting beneficial vasodilation while reducing neuroinflammatory NO production
- Growth hormone receptor upregulation: Increases expression of growth hormone receptors, enhancing the trophic and regenerative effects of endogenous growth hormone on neural tissue
- Dopamine system stabilisation: Modulates the dopaminergic system bidirectionally, counteracting both dopamine excess and depletion-related dysfunction
- Serotonin synthesis: Enhances serotonin synthesis in specific brain regions, supporting mood and stress resilience
- GABAergic modulation: Influences GABAergic transmission, contributing to anxiolytic and neuroprotective effects
- Angiogenesis promotion: Stimulates VEGF-mediated formation of new blood vessels, improving blood supply to damaged tissue including brain regions
- Oral dosage: 250-500 mcg (micrograms) per day, taken on an empty stomach. Oral BPC-157 is increasingly popular as it is stable in gastric acid
- Subcutaneous injection: 250-500 mcg per day, typically near the site of injury or subcutaneously in the abdomen. Injection provides higher systemic bioavailability
- Nasal spray: Intranasal administration (250-500 mcg) used for targeted brain effects
- Cycling: Common protocols use 4-8 weeks on, followed by a break of similar duration
- Onset: Tissue healing effects may be noticed within days. Cognitive and mood effects typically develop over 1-4 weeks
- Limited human trial data: While over 100 animal studies exist, published human clinical trials are very limited. Most human evidence is anecdotal
- Animal safety profile: No lethal dose has been established in animal studies, and no significant toxicity has been reported at any dose tested
- Cancer concern: BPC-157 promotes angiogenesis and growth factor signalling. Individuals with active cancer or high cancer risk should exercise extreme caution as these mechanisms could theoretically promote tumour growth
- Regulatory status: Not approved as a medicine in any jurisdiction. Sold as a "research peptide." Quality and purity vary significantly between suppliers
- Pregnancy and breastfeeding: No safety data exists. Avoid during pregnancy and breastfeeding
Natural Sources & Forms
- Oral capsules: BPC-157 in acid-stable capsule form, available from peptide and nootropic retailers
- Lyophilised powder for injection: Reconstituted with bacteriostatic water for subcutaneous injection. Requires sterile technique
- Nasal spray: Pre-made nasal spray formulations available from some vendors
- Quality note: Purchase only from reputable suppliers who provide third-party testing certificates of analysis (COAs) for purity and identity
Frequently Asked Questions
A synthetic peptide derived from a naturally occurring gastric protein - researched for remarkable tissue repair, neuroprotection, and gut-brain axis modulation, increasingly used in the biohacking community for cognitive recovery.
The key benefits of BPC-157 include: Anxiety & Calm, Cognitive Enhancement, Energy, Longevity, Mood, Stress Relief.
Nitric oxide system modulation: Interacts with both eNOS (protective) and iNOS (inflammatory) pathways, promoting beneficial vasodilation while reducing neuroinflammatory NO production Growth hormone receptor upregulation: Increases expression of growth hormone receptors, enhancing the trophic and regenerative effects of endogenous growth hormone on neural tissue Dopamine system stabilisation: Modulates the dopaminergic system bidirectionally, counteracting both dopamine excess and depletion-related dysfunction Serotonin synthesis: Enhances serotonin synthesis in specific brain regions, supporting mood and stress resilience GABAergic modulation: Influences GABAergic transmission, contributing to anxiolytic and neuroprotective effects Angiogenesis promotion: Stimulates VEGF-mediated formation of new blood vessels, improving blood supply to damaged tissue including brain regions
Oral dosage: 250-500 mcg (micrograms) per day, taken on an empty stomach. Oral BPC-157 is increasingly popular as it is stable in gastric acid Subcutaneous injection: 250-500 mcg per day, typically near the site of injury or subcutaneously in the abdomen. Injection provides higher systemic bioavailability Nasal spray: Intranasal administration (250-500 mcg) used for targeted brain effects Cycling: Common protocols use 4-8 weeks on, followed by a break of similar duration Onset: Tissue healing effects may be noticed within days. Cognitive and mood effects typically develop over 1-4 weeks
Limited human trial data: While over 100 animal studies exist, published human clinical trials are very limited. Most human evidence is anecdotal Animal safety profile: No lethal dose has been established in animal studies, and no significant toxicity has been reported at any dose tested Cancer concern: BPC-157 promotes angiogenesis and growth factor signalling. Individuals with active cancer or high cancer risk should exercise extreme caution as these mechanisms could theoretically promote tumour growth Regulatory status: Not approved as a medicine in any jurisdiction. Sold as a "research peptide." Quality and purity vary significantly between suppliers Pregnancy and breastfeeding: No safety data exists. Avoid during pregnancy and breastfeeding
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!